KALA BIO, Inc. — Director's Dealing 2017

Nov 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-11-20

Reporting Person: Bazemore Todd (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-20	Stock Option (right to buy)	$19.60	A	172000	Acquired	2027-11-19	Common Stock (172000)	Direct

Footnotes

F1: This option was granted on November 20, 2017 and vests over four years, with 25% of the shares underlying the option vesting on November 20, 2018, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.